An experimental vaccine against the virus that causes most cancers of the cervix has passed—with flying colors—a test typically needed for regulatory approval.
The vaccine targets four strains of the sexually transmitted human papillomavirus (HPV), which infects about 20 million men and women in the United States.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.